A lackluster earnings announcement from NATCO Pharma Limited (NSE:NATCOPHARM) last week didn't sink the stock price. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.
In order to understand the potential for per share returns, it is essential to consider how much a company is diluting shareholders. NATCO Pharma expanded the number of shares on issue by 9.5% over the last year. That means its earnings are split among a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out NATCO Pharma's historical EPS growth by clicking on this link.
Unfortunately, NATCO Pharma's profit is down 27% per year over three years. Even looking at the last year, profit was still down 46%. Sadly, earnings per share fell further, down a full 46% in that time. So you can see that the dilution has had a bit of an impact on shareholders.
In the long term, if NATCO Pharma's earnings per share can increase, then the share price should too. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
NATCO Pharma issued shares during the year, and that means its EPS performance lags its net income growth. Because of this, we think that it may be that NATCO Pharma's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. For example - NATCO Pharma has 1 warning sign we think you should be aware of.
Today we've zoomed in on a single data point to better understand the nature of NATCO Pharma's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.